Multikine is back in Phase 3, but can CEL-SCI turn a striking subgroup signal into approval?
CEL-SCI launches a 212-patient Multikine Phase 3 study, but subgroup validation, funding and regulatory execution remain decisive.
Pharma & Biotech
Pharma & Biotech
Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown
Cryo-Cell avoided immediate delisting pressure. The harder test is whether its cord blood banking model can repair the balance sheet by 2027.